CLINICAL_TRIALS
research
· 2024-10-15
Clinical Trial Update: Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy [Phase 2]
Summary
A Phase 2 clinical study evaluating CM338 for IgA nephropathy is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Keymed Biosciences Co.Ltd | Conditions: IgA Nephropathy | Phase 2 | Status: RECRUITING